Sodium oxybate in the treatment of alcohol dependence: From the alcohol withdrawal syndrome to the alcohol relapse prevention

Katrin Skala, Fabio Caputo, Antonio Mirijello, Gabriele Vassallo, Mariangela Antonelli, Anna Ferrulli, Henriette Walter, Otto Lesch, Giovanni Addolorato

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Introduction: Sodium oxybate (SMO) has been shown to be safe and effective in the treatment of patients with alcohol use disorders (AUDs); it was approved in Italy and Austria for the treatment of alcohol withdrawal syndrome and for relapse prevention. The focus of this review is to discuss the clinical evidence on the therapeutic potential of SMO for AUDs. Areas covered: This review covers the studies in patients with alcohol withdrawal syndrome who received SMO for the treatment of withdrawal symptoms and the studies in patients with AUDs who received SMO to achieve total alcohol abstinence, reduction of alcohol intake, and relapse prevention. Relevant medical literature on SMO was identified by searching databases including MEDLINE and EMBASE (searches last updated 20 September 2013), bibliographies from published literature, clinical trial registries/databases, and websites. Expert opinion: SMO has proved safe and effective in the treatment of alcohol withdrawal syndrome and in the prevention of relapses. Craving for and abuse of SMO have been reported, in particular in some subtypes of alcoholic patients, e.g., those affected by co-Addiction and/or psychiatric comorbidity. Future multicenter, multinational, randomized clinical trials should be useful to optimize the treatments in relation with patients' characteristics, for example, pharmacogenetic, neurobiological, and psychological.

Original languageEnglish
Pages (from-to)245-257
Number of pages13
JournalExpert Opinion on Pharmacotherapy
Volume15
Issue number2
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Sodium Oxybate
Secondary Prevention
Alcoholism
Alcohols
Therapeutics
Alcohol Abstinence
Databases
Substance Withdrawal Syndrome
Austria
Pharmacogenetics
Expert Testimony
Bibliography
Alcoholics
MEDLINE
Italy
Psychiatry
Registries
Comorbidity
Randomized Controlled Trials
Clinical Trials

Keywords

  • Alcoholism
  • Gamma-hydroxybutyric acid
  • GHB
  • SMO

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Sodium oxybate in the treatment of alcohol dependence : From the alcohol withdrawal syndrome to the alcohol relapse prevention. / Skala, Katrin; Caputo, Fabio; Mirijello, Antonio; Vassallo, Gabriele; Antonelli, Mariangela; Ferrulli, Anna; Walter, Henriette; Lesch, Otto; Addolorato, Giovanni.

In: Expert Opinion on Pharmacotherapy, Vol. 15, No. 2, 02.2014, p. 245-257.

Research output: Contribution to journalArticle

Skala, Katrin ; Caputo, Fabio ; Mirijello, Antonio ; Vassallo, Gabriele ; Antonelli, Mariangela ; Ferrulli, Anna ; Walter, Henriette ; Lesch, Otto ; Addolorato, Giovanni. / Sodium oxybate in the treatment of alcohol dependence : From the alcohol withdrawal syndrome to the alcohol relapse prevention. In: Expert Opinion on Pharmacotherapy. 2014 ; Vol. 15, No. 2. pp. 245-257.
@article{0e74e194b2424dfda773c73774e943cb,
title = "Sodium oxybate in the treatment of alcohol dependence: From the alcohol withdrawal syndrome to the alcohol relapse prevention",
abstract = "Introduction: Sodium oxybate (SMO) has been shown to be safe and effective in the treatment of patients with alcohol use disorders (AUDs); it was approved in Italy and Austria for the treatment of alcohol withdrawal syndrome and for relapse prevention. The focus of this review is to discuss the clinical evidence on the therapeutic potential of SMO for AUDs. Areas covered: This review covers the studies in patients with alcohol withdrawal syndrome who received SMO for the treatment of withdrawal symptoms and the studies in patients with AUDs who received SMO to achieve total alcohol abstinence, reduction of alcohol intake, and relapse prevention. Relevant medical literature on SMO was identified by searching databases including MEDLINE and EMBASE (searches last updated 20 September 2013), bibliographies from published literature, clinical trial registries/databases, and websites. Expert opinion: SMO has proved safe and effective in the treatment of alcohol withdrawal syndrome and in the prevention of relapses. Craving for and abuse of SMO have been reported, in particular in some subtypes of alcoholic patients, e.g., those affected by co-Addiction and/or psychiatric comorbidity. Future multicenter, multinational, randomized clinical trials should be useful to optimize the treatments in relation with patients' characteristics, for example, pharmacogenetic, neurobiological, and psychological.",
keywords = "Alcoholism, Gamma-hydroxybutyric acid, GHB, SMO",
author = "Katrin Skala and Fabio Caputo and Antonio Mirijello and Gabriele Vassallo and Mariangela Antonelli and Anna Ferrulli and Henriette Walter and Otto Lesch and Giovanni Addolorato",
year = "2014",
month = "2",
doi = "10.1517/14656566.2014.863278",
language = "English",
volume = "15",
pages = "245--257",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Sodium oxybate in the treatment of alcohol dependence

T2 - From the alcohol withdrawal syndrome to the alcohol relapse prevention

AU - Skala, Katrin

AU - Caputo, Fabio

AU - Mirijello, Antonio

AU - Vassallo, Gabriele

AU - Antonelli, Mariangela

AU - Ferrulli, Anna

AU - Walter, Henriette

AU - Lesch, Otto

AU - Addolorato, Giovanni

PY - 2014/2

Y1 - 2014/2

N2 - Introduction: Sodium oxybate (SMO) has been shown to be safe and effective in the treatment of patients with alcohol use disorders (AUDs); it was approved in Italy and Austria for the treatment of alcohol withdrawal syndrome and for relapse prevention. The focus of this review is to discuss the clinical evidence on the therapeutic potential of SMO for AUDs. Areas covered: This review covers the studies in patients with alcohol withdrawal syndrome who received SMO for the treatment of withdrawal symptoms and the studies in patients with AUDs who received SMO to achieve total alcohol abstinence, reduction of alcohol intake, and relapse prevention. Relevant medical literature on SMO was identified by searching databases including MEDLINE and EMBASE (searches last updated 20 September 2013), bibliographies from published literature, clinical trial registries/databases, and websites. Expert opinion: SMO has proved safe and effective in the treatment of alcohol withdrawal syndrome and in the prevention of relapses. Craving for and abuse of SMO have been reported, in particular in some subtypes of alcoholic patients, e.g., those affected by co-Addiction and/or psychiatric comorbidity. Future multicenter, multinational, randomized clinical trials should be useful to optimize the treatments in relation with patients' characteristics, for example, pharmacogenetic, neurobiological, and psychological.

AB - Introduction: Sodium oxybate (SMO) has been shown to be safe and effective in the treatment of patients with alcohol use disorders (AUDs); it was approved in Italy and Austria for the treatment of alcohol withdrawal syndrome and for relapse prevention. The focus of this review is to discuss the clinical evidence on the therapeutic potential of SMO for AUDs. Areas covered: This review covers the studies in patients with alcohol withdrawal syndrome who received SMO for the treatment of withdrawal symptoms and the studies in patients with AUDs who received SMO to achieve total alcohol abstinence, reduction of alcohol intake, and relapse prevention. Relevant medical literature on SMO was identified by searching databases including MEDLINE and EMBASE (searches last updated 20 September 2013), bibliographies from published literature, clinical trial registries/databases, and websites. Expert opinion: SMO has proved safe and effective in the treatment of alcohol withdrawal syndrome and in the prevention of relapses. Craving for and abuse of SMO have been reported, in particular in some subtypes of alcoholic patients, e.g., those affected by co-Addiction and/or psychiatric comorbidity. Future multicenter, multinational, randomized clinical trials should be useful to optimize the treatments in relation with patients' characteristics, for example, pharmacogenetic, neurobiological, and psychological.

KW - Alcoholism

KW - Gamma-hydroxybutyric acid

KW - GHB

KW - SMO

UR - http://www.scopus.com/inward/record.url?scp=84892185974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892185974&partnerID=8YFLogxK

U2 - 10.1517/14656566.2014.863278

DO - 10.1517/14656566.2014.863278

M3 - Article

C2 - 24283802

AN - SCOPUS:84892185974

VL - 15

SP - 245

EP - 257

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 2

ER -